HLA-DRB7: A Drug Target / Disease Biomarker (G3129)

Target Name: HLA-DRB7

NCBI ID: G3129

HLA-DRB7

Other Name(s): major histocompatibility complex, class II, DR beta 7 (pseudogene) | Major histocompatibility complex, class II, DR beta 7 (pseudogene)

HLA-DRB7: A Drug Target / Disease Biomarker

HLA-DRB7 is a human leukocyte antigen (HLA) that is expressed in the majority of human tissues and is involved in the immune response. It is a member of the DRB7 cluster of HLA-DRB family proteins and is characterized by the presence of a variable region (V) and a constant region (C). HLA-DRB7 is known to play a crucial role in the regulation of immune responses and has been implicated in a number of diseases, including autoimmune disorders, cancer, and neurodegenerative diseases.

One of the key features of HLA-DRB7 is its ability to interact with other immune molecules, including the T cell receptor (TCR) and the MyD88 receptor. These interactions enable HLA-DRB7 to regulate the activity of T cells, which are critical for immune surveillance of the body against infection and disease.

HLA-DRB7 is also involved in the regulation of inflammation and has been shown to play a key role in the development of inflammatory diseases, such as rheumatoid arthritis, Crohn's disease, and multiple sclerosis. In these diseases, HLA-DRB7 is expressed in the immune cells that are responsible for the inflammation and is thought to contribute to the development and progression of these conditions.

Another potential drug target for HLA-DRB7 is its role in cancer. HLA-DRB7 is often overexpressed in cancer cells and has been shown to promote the growth and survival of these cells. Therefore, targeting HLA-DRB7 with drugs that can inhibit its activity may be an effective way to treat cancer.

HLA-DRB7 is also an attractive biomarker for cancer diagnosis and monitoring. The expression of HLA-DRB7 in cancer cells can be used as a indicator of disease status and response to treatment. HLA-DRB7 levels have been shown to be elevated in a variety of cancer types, including breast, lung, and ovarian cancer, and have been used as a biomarker for these conditions.

In addition to its potential as a drug target and biomarker, HLA-DRB7 is also of interest to researchers because of its role in the immune response. HLA-DRB7 is a key molecule in the immune response and is involved in the regulation of T cell activity. Therefore, studying HLA-DRB7 is essential for understanding the immune system and how it functions.

In conclusion, HLA-DRB7 is a drug target and biomarker that has the potential to revolutionize our understanding of the immune system and its role in disease. Further research is needed to fully understand the role of HLA-DRB7 in the immune response and its potential as a drug.

Protein Name: Major Histocompatibility Complex, Class II, DR Beta 7 (pseudogene)

The "HLA-DRB7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA-DRB7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets